What is porocarcinoma?
Porocarcinoma, also called eccrine porocarcinoma or malignant eccrine poroma, is a rare skin cancer that starts in a sweat gland duct. It develops from cells lining the part of the duct that runs through the top layer of the skin (the acrosyringium).
It is one of the adnexal carcinomas, a group of cancers arising from skin structures such as sweat glands and hair follicles. Porocarcinoma is very uncommon, accounting for only about 0.005-0.01% of skin tumours (Salih et al., 2017).
It mainly affects older adults, most often in their 60s to 80s. It usually appears on the legs and feet, the head and neck, or the trunk. Some porocarcinomas develop within a long-standing benign poroma, a harmless sweat duct growth (Robson et al., 2001).
Porocarcinoma can look like more common skin problems, such as a wart, basal cell carcinoma or squamous cell carcinoma, so it is often recognised only after a biopsy.
Most porocarcinomas are cured by surgery. A minority spread to the lymph nodes or further, and in these cases the outlook is more serious (Nazemi et al., 2018).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Malignant sweat duct (adnexal) carcinoma of the skin |
| How common | Very rare; about 0.005-0.01% of skin tumours |
| Typical age | Mostly 60-80 years |
| Common sites | Legs and feet, head and neck, trunk, arms |
| Appearance | Red, pink or skin-coloured lump or plaque, often ulcerated or bleeding |
| Key test | Skin biopsy |
| Main treatment | Wide local excision or Mohs surgery |
| Typical spread | Skin around the tumour, lymph nodes; less often lungs, liver, bone |
| Outlook | Very good when localised; serious if it has spread |
2. Causes and risk factors
The exact cause is not known. Several factors may play a role.
| Risk factor | Notes |
|---|---|
| Older age | Most people are over 60 |
| Long-standing poroma | Some porocarcinomas arise from a benign poroma |
| Sun exposure | May contribute, especially for head and neck tumours |
| Weakened immune system | For example after organ transplant or with chronic lymphocytic leukaemia |
| Radiation exposure | Previous radiotherapy to the skin has been reported |
| Chronic skin damage | Scars or long-term inflammation in rare cases |
Gene changes
Many poromas and porocarcinomas carry YAP1 gene fusions, such as YAP1::MAML2 and YAP1::NUTM1 (Sekine et al., 2019). These changes arise in the tumour only and are not inherited. Tumours with a NUTM1 fusion can be detected with a NUT stain, which helps the diagnosis.
Other gene changes, such as TP53 and RAS mutations and changes caused by ultraviolet light, are also found in some porocarcinomas.
Porocarcinoma and the poroma family
Porocarcinoma belongs to a family of sweat duct tumours. Most members of this family are benign.
| Tumour | Behaviour | Notes |
|---|---|---|
| Poroma | Benign | A common, slow-growing lump, often on the sole of the foot or the palm |
| Hidroacanthoma simplex | Benign | A poroma confined to the top layer of the skin |
| Dermal duct tumour | Benign | A poroma within the deeper skin |
| Poroid hidradenoma | Benign | A poroma-related tumour with cystic areas |
| Porocarcinoma | Malignant | The cancerous member of the group |
Because a benign poroma and porocarcinoma can share the same gene fusions, researchers believe that some porocarcinomas develop from a poroma that gains further changes over time.
3. How does it look
On the skin
| Feature | Description |
|---|---|
| Shape | A raised lump (nodule), a flat or slightly raised patch (plaque) or a polyp-like growth |
| Colour | Red, pink, skin-coloured, sometimes brown or black (pigmented) |
| Surface | Smooth, warty, crusted or ulcerated |
| Size | Often 1-3 cm, but can be larger |
| Bleeding | Bleeds easily after minor injury |
| Growth | May change slowly for years, then grow quickly |
| Satellite lesions | Small nearby nodules in some cases, a sign of local spread |
A sudden change in a long-standing lump, such as rapid growth, bleeding, ulceration or pain, can be a sign that a benign poroma has become malignant.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Small, uniform “poroid” cells and larger “cuticular” cells |
| Ducts | Small duct structures lined by cells that stain with CEA or EMA |
| Architecture | Tumour islands extending from the epidermis into the dermis |
| Malignant features | Abnormal nuclei, many mitoses, necrosis, infiltrative edges |
| Pagetoid spread | Tumour cells scattered within the overlying epidermis in some cases |
| Special stains | CEA and EMA (ducts); NUT in YAP1::NUTM1 tumours |
High-risk features
Robson and colleagues identified features linked with a worse outlook (Robson et al., 2001):
| Feature | Significance |
|---|---|
| Mitotic count above 14 per high-power field | Faster-growing tumour |
| Tumour depth more than 7 mm | Higher risk of spread |
| Lymphovascular invasion | Tumour cells in lymph or blood vessels |
| Infiltrative growth | Higher risk of local recurrence |
4. Symptoms
Common symptoms
- A lump or growth on the skin that is new or changing
- Bleeding from the lump, sometimes after minor knocks
- Ulceration or a sore that does not heal
- Crusting or oozing
- Itching or tenderness
- Pain, especially when the tumour is on the foot
Symptoms of spread
| Site | Possible symptoms |
|---|---|
| Nearby skin | New small nodules around the original tumour or scar |
| Lymph nodes | Swollen lumps in the groin, armpit or neck |
| Lungs | Cough or breathlessness |
| Liver | Tummy discomfort, jaundice (rare) |
| Bone | Bone pain |
When to seek medical advice
See a doctor or dermatologist about any skin lump that is:
- New and does not go away within a few weeks
- Growing, changing shape or colour
- Bleeding, crusting or ulcerated
- A long-standing lump that has suddenly changed
Early assessment allows a simpler operation and a better outcome.
5. Diagnosis
| Test | Purpose |
|---|---|
| Skin examination and dermoscopy | Looks at the lump in detail |
| Skin biopsy | Confirms the diagnosis; excision or deep punch biopsy preferred |
| Immunohistochemistry | CEA, EMA, NUT and other stains |
| Lymph node examination | Checks for swollen nodes |
| Ultrasound of lymph nodes | Looks for spread; with needle biopsy if suspicious |
| Sentinel lymph node biopsy | Considered for high-risk tumours |
| CT or PET-CT | For high-risk tumours or suspected spread |
A shallow biopsy can miss the deeper malignant parts, so a sample that includes the full thickness of the lesion is important.
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Poroma | Benign; no malignant features |
| Squamous cell carcinoma | Common skin cancer; no sweat duct structures |
| Basal cell carcinoma | Common, slow-growing; different microscopic features |
| Amelanotic melanoma | Melanoma markers (SOX10, Melan-A) positive |
| Pyogenic granuloma | Benign, fast-growing blood vessel growth |
| Metastases from other cancers | Spread from internal organs; history and stains differ |
6. Treatment
Treatment is planned by a skin cancer team, often including dermatologists, plastic surgeons and oncologists.
Surgery
Surgery is the main treatment and cures most localised porocarcinomas.
| Approach | Notes |
|---|---|
| Wide local excision | Removes the tumour with a margin of healthy skin, often 1-2 cm |
| Mohs micrographic surgery | Removes the tumour layer by layer with immediate margin checks; useful on the face, hands and feet |
| Skin graft or flap | Used to close larger wounds |
| Re-excision | If the first excision did not clear the tumour |
Mohs surgery has been associated with low recurrence rates in published series (Nazemi et al., 2018).
The features seen under the microscope, such as tumour depth and infiltrative growth, can help surgeons decide how wide a margin is needed and whether further staging is worthwhile (Belin et al., 2011).
Lymph nodes
| Situation | Approach |
|---|---|
| High-risk tumour, no swollen nodes | Sentinel lymph node biopsy may be offered |
| Cancer in lymph nodes | Lymph node dissection, often followed by radiotherapy |
Radiotherapy
Radiotherapy may be used:
- After surgery when margins are close or the tumour is high risk
- After lymph node dissection
- When surgery is not possible, for example in frail people
- To relieve symptoms from metastases
Treatment of advanced disease
There is no standard treatment for metastatic porocarcinoma, because it is so rare.
| Option | Notes |
|---|---|
| Chemotherapy | Platinum-based, taxanes or other regimens; responses are usually short-lived |
| Immunotherapy | Checkpoint inhibitors such as pembrolizumab; striking responses have been reported in individual patients (Lee et al., 2019) |
| Targeted therapy | Being explored based on the tumour’s gene changes |
| Clinical trials | Recommended where available |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Skin surgery | Usually done under local anaesthetic as a day case |
| Mohs surgery | Several hours in the clinic while each layer is checked; the wound is closed the same day or soon after |
| Larger operations | General anaesthetic and a short hospital stay, especially if a graft, flap or lymph node surgery is needed |
| Wound care | Dressings changed by a nurse; stitches removed after 1-2 weeks |
| Leg and foot wounds | Keeping the leg raised and avoiding long periods of standing helps healing |
| Radiotherapy (if needed) | Short daily treatments over a few weeks |
Most people return to their normal routine within a few weeks. Healing on the lower leg can take longer, particularly in older people or those with diabetes or poor circulation.
Side effects
| Treatment | Possible side effects |
|---|---|
| Skin surgery | Pain, scarring, wound infection, slow healing on the legs and feet |
| Lymph node surgery | Swelling of the limb (lymphoedema), numbness, wound fluid collection |
| Radiotherapy | Skin redness, peeling, tiredness, later skin thinning |
| Immunotherapy | Tiredness, rash, and inflammation of organs such as the bowel, lungs or thyroid |
7. Outlook (prognosis)
| Situation | Approximate outlook |
|---|---|
| Localised and completely removed | Excellent; most people are cured |
| Local recurrence | Occurs in about 1 in 5 in older series; usually treatable with further surgery (Robson et al., 2001) |
| Lymph node spread | Seen in about 1 in 5; outlook becomes more serious |
| Distant spread | Uncommon; historically associated with poor survival |
In the Robson series of 69 patients, people with lymph node spread had a considerably higher risk of dying from the disease. Tumour depth, mitotic rate and lymphovascular invasion were the strongest warning signs. Many people with porocarcinoma are elderly and die of other causes.
The best way to improve the outlook is early diagnosis. A lump that is removed while it is still small and shallow is very unlikely to spread, so any changing skin growth in an older person deserves a prompt biopsy.
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Skin and scar checks | Every 3-6 months at first, to detect local recurrence |
| Lymph node examination | Checks for swollen nodes |
| Full skin examination | Many patients have other skin cancers |
| Imaging | For high-risk tumours or new symptoms |
Follow-up usually continues for at least 5 years, and longer for high-risk tumours.
9. Living with porocarcinoma
- Check your skin monthly, including the scar and nearby skin
- Feel for lumps in the groin, armpits or neck, depending on the tumour site
- Protect your skin from the sun with clothing, shade and sunscreen
- Look after wounds on the legs and feet; healing can be slow, especially with diabetes or poor circulation
- Ask about lymphoedema care if you had lymph node surgery
- Report changes early to your skin cancer team
- Keep a photo record of the scar and any other skin spots, so changes are easier to notice
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is porocarcinoma a type of melanoma? | No. It is a sweat duct cancer, though rare pigmented forms can look like melanoma |
| Can a poroma turn into porocarcinoma? | Rarely, yes. A changing poroma should be checked |
| Is it caused by sweating? | No. It arises from cells of the sweat duct, but sweating does not cause it |
| Is it inherited? | No |
| Will I need chemotherapy? | Usually not; surgery cures most people |
| Why did it take a long time to diagnose? | It is rare and can look like common, harmless skin growths until a biopsy is done |
| Do I need scans? | Only for high-risk tumours or if there are signs of spread |
| Can it come back? | Yes, sometimes, so follow-up checks are important |
11. Questions to ask your care team
- Was the tumour completely removed with clear margins?
- Does it have high-risk features such as depth or lymphovascular invasion?
- Should I have a sentinel lymph node biopsy or scans?
- Would Mohs surgery be suitable for me?
- How often should I have check-ups?
- What signs of recurrence should I look for?
Resources
- Belin, E. et al. (2011) ‘Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure’, British Journal of Dermatology, 165(5), pp. 985-989.
- Lee, K.A. et al. (2019) ‘Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab’, BMJ Case Reports, 12(9), e228917.
- Nazemi, A. et al. (2018) ‘Eccrine porocarcinoma: new insights and a systematic review of the literature’, Dermatologic Surgery, 44(10), pp. 1247-1261.
- Robson, A. et al. (2001) ‘Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases’, American Journal of Surgical Pathology, 25(6), pp. 710-720.
- Salih, A.M. et al. (2017) ‘Porocarcinoma: presentation and management, a meta-analysis of 453 cases’, Annals of Medicine and Surgery, 20, pp. 74-79.
- Sekine, S. et al. (2019) ‘Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma’, Journal of Clinical Investigation, 129(9), pp. 3827-3832.
- National Cancer Institute (2026) Skin Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/skin/hp/skin-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.